De novo Drug Delivery Modalities for Treating Damaged Hearts: Current Challenges and Emerging Solutions

Area of Science:

• Cardiovascular Medicine
• Nanotechnology
• Biomaterials Science

Background:

• Cardiovascular disease (CVD) is the primary cause of global mortality, with acute myocardial infarction (MI) being the leading cause of death.
• Existing CVD treatments have advanced, yet there is a continuous need for novel therapeutic strategies.
• Nanomedicine and nanotechnology present a promising frontier for cardiac repair through enhanced drug delivery.

Purpose of the Study:

• To review the application of nanomedicine in treating myocardial damage post-MI.
• To highlight advanced drug delivery systems for cardiovascular therapeutics.
• To assess the potential of nanoparticles, microspheres, and hydrogels in cardiac repair.

Main Methods:

• Review of current literature on nanomedicine applications in cardiovascular therapy.
• Focus on drug delivery systems targeting injured myocardial tissue.
• Analysis of therapeutic agents like growth factors, stem cells, and exosomes delivered via nanomaterials.

Main Results:

• Nanoparticles, microspheres, and hydrogels demonstrate potential for targeted delivery of therapeutics to the myocardium.
• These advanced delivery systems can improve the efficacy of treatments for damaged heart tissue.
• Successful delivery of growth factors, stem cells, and exosomes has shown promise in enhancing cardiac function.

Conclusions:

• Nanomedicine provides a transformative approach to treating cardiovascular disease, especially after myocardial infarction.
• Targeted drug delivery using nanoparticles, microspheres, and hydrogels is crucial for improving cardiac function.
• Further research into these nanotechnologies holds significant potential for developing next-generation cardiac therapies.